T cell receptor-engineered T cell (TCR-T) therapy is rapidly emerging as a promising frontier in cancer treatment. By reprogramming a patient’s own T cells to recognize specific antigens on tumor cells, TCR-T therapies offer a highly personalized approach to targeting and eliminating cancer. Unlike chimeric antigen receptor (CAR) T cell therapies, which predominantly target cell-surface […]
